CAS Number 83480-29-9 ChemSpider 392046 KEGG D01665 Formula C10H21NO7 ATC code A10BF03 (WHO) | PubChem CID 444020 UNII S77P977AG8 Molar mass 267.28 g/mol DrugBank DB04878 | |
 | ||
AHFS/Drugs.com International Drug Names | ||
Voglibose (INN and USAN, trade name Voglib, marketed by Mascot Health Series) is an alpha-glucosidase inhibitor used for lowering post-prandial blood glucose levels in people with diabetes mellitus. Voglibose delays the absorption of glucose thereby reducing the risk of macrovascular complications. Voglibose is a research product of Takeda Pharmaceutical Company, Japan's largest pharmaceutical company. Voglibose was first launched in 1994, under the trade name BASEN, to improve postprandial hyperglycemia in diabetes mellitus.
Postprandial hyperglycemia (PPHG) is primarily due to first phase insulin secretion. Alpha glucosidase inhibitors delay glucose absorption at the intestine level and thereby prevent sudden surge of glucose after a meal.
There are three drugs which belong to this class, acarbose, miglitol and voglibose, of which voglibose is the newest.